Seroatlas · Human Serome Atlas

PRLHR

Prolactin-releasing peptide receptor

Also known as: GPR10, PRLHR_HUMAN, PrRPR

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P49683
Gene: PRLHR
Ensembl: ENSG00000119973
Chromosome: 10
Canonical length: 370 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable neuropeptide binding activity and neuropeptide receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Predicted to act upstream of or within feeding behavior and hormone metabolic process. Located in cilium. Implicated in hypertension. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

370 residues, UniProt reviewed canonical sequence.

>P49683|PRLHR
     1  MASSTTRGPR VSDLFSGLPP AVTTPANQSA EASAGNGSVA GADAPAVTPF QSLQLVHQLK
    61  GLIVLLYSVV VVVGLVGNCL LVLVIARVRR LHNVTNFLIG NLALSDVLMC TACVPLTLAY
   121  AFEPRGWVFG GGLCHLVFFL QPVTVYVSVF TLTTIAVDRY VVLVHPLRRR ISLRLSAYAV
   181  LAIWALSAVL ALPAAVHTYH VELKPHDVRL CEEFWGSQER QRQLYAWGLL LVTYLLPLLV
   241  ILLSYVRVSV KLRNRVVPGC VTQSQADWDR ARRRRTFCLL VVIVVVFAVC WLPLHVFNLL
   301  RDLDPHAIDP YAFGLVQLLC HWLAMSSACY NPFIYAWLHD SFREELRKLL VAWPRKIAPH
   361  GQNMTVSVVI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRLHR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 6.3 nTPM

Expression across tissuesHPA

Tissue

pituitary gland: 6.3 nTPM
adrenal gland: 4.9 nTPM
endometrium: 4.6 nTPM
smooth muscle: 3.2 nTPM
vagina: 2.9 nTPM
hypothalamus: 2.6 nTPM

Single-cell type

gonadotrophs: 48 nCPM
adrenal medulla cells: 32 nCPM
other brain neurons: 9 nCPM
lactotrophs: 7 nCPM
astrocytes: 5.3 nCPM
brain inhibitory neurons: 4.3 nCPM

Immune cell

neutrophil: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

pons: 28 nTPM
midbrain: 16 nTPM
hypothalamus: 15 nTPM
thalamus: 12 nTPM
cerebral cortex: 11 nTPM
basal ganglia: 8.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.48
gnomAD pLI: 0
gnomAD missense Z: -0.41
DepMap mean gene effect: -0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

G protein-coupled receptor, rhodopsin-like
GPCR, rhodopsin-like, 7TM
7 transmembrane receptor (rhodopsin family)
Prolactin-releasing peptide receptor

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRLHR as an antibody target. Whether an autoantibody or antibody against PRLHR could matter depends on whether native PRLHR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRLHR is annotated at the cell surface, where native PRLHR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PRLHR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...